Module

Neoadjuvant Treatment for Breast Cancer

Source: Breast Cancer Annual Update 2005

Neoadjuvant Treatment for Breast Cancer


CME Program Director: Clifford A. Hudis, MD

Faculty:

  • Clifford A. Hudis, MD

CME CREDIT INFORMATION

Release Date: 11/15/05

Expiration Date: 11/14/06


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.5 Nursing CE credits

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Compare the advantages and disadvantages of neoadjuvant vs adjuvant therapy.
  • Describe the most recent data using newer agents, including aromatase inhibitors and targeted therapies, in the neoadjuvant setting.
  • Discuss molecular predictors of response to neoadjuvant therapy.

Topics covered include:

  • Introduction
  • Outcomes—Neoadjuvant vs Adjuvant Chemotherapy
  • Taxane-Based Regimens in the Neoadjuvant Setting
  • Aromatase Inhibitors in the Neoadjuvant Setting
  • Targeted Therapy
  • Novel Chemotherapy Agents
  • Predictors of Response to Neoadjuvant Therapy
  • Sequencing of Neoadjuvant Chemotherapy and Sentinel Lymph Node Biopsy
  • Summary—Implications for Clinical Application
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.